Citigroup Inc. decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 4.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,948 shares of the specialty pharmaceutical company’s stock after selling 3,928 shares during the period. Citigroup Inc. owned 0.15% of Jazz Pharmaceuticals worth $13,601,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in JAZZ. Spire Wealth Management lifted its holdings in Jazz Pharmaceuticals by 957.9% in the first quarter. Spire Wealth Management now owns 201 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 182 shares during the period. UMB Bank n.a. boosted its position in shares of Jazz Pharmaceuticals by 70.4% during the 1st quarter. UMB Bank n.a. now owns 271 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 112 shares in the last quarter. Huntington National Bank boosted its position in shares of Jazz Pharmaceuticals by 37.9% during the 4th quarter. Huntington National Bank now owns 324 shares of the specialty pharmaceutical company’s stock valued at $52,000 after purchasing an additional 89 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth approximately $53,000. Finally, IFP Advisors Inc lifted its stake in Jazz Pharmaceuticals by 26.5% in the fourth quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock valued at $64,000 after buying an additional 75 shares during the period. 88.15% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on JAZZ shares. Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $204.00 to $217.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. StockNews.com initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, August 17th. They set a “strong-buy” rating on the stock. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $203.00 to $201.00 and set an “outperform” rating for the company in a research note on Thursday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $204.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, August 11th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average target price of $206.67.
Check Out Our Latest Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ JAZZ opened at $143.71 on Wednesday. The stock has a market cap of $9.07 billion, a price-to-earnings ratio of -91.54, a PEG ratio of 1.01 and a beta of 0.73. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.49 and a current ratio of 3.18. Jazz Pharmaceuticals plc has a fifty-two week low of $120.64 and a fifty-two week high of $160.96. The firm’s 50-day simple moving average is $130.92 and its 200 day simple moving average is $135.65.
Insider Transactions at Jazz Pharmaceuticals
In related news, EVP Neena M. Patil sold 750 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $139.59, for a total transaction of $104,692.50. Following the transaction, the executive vice president now owns 30,686 shares of the company’s stock, valued at $4,283,458.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Neena M. Patil sold 1,600 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $127.98, for a total transaction of $204,768.00. Following the sale, the executive vice president now directly owns 32,826 shares in the company, valued at $4,201,071.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 750 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $139.59, for a total value of $104,692.50. Following the sale, the executive vice president now owns 30,686 shares in the company, valued at $4,283,458.74. The disclosure for this sale can be found here. Insiders sold a total of 3,875 shares of company stock valued at $518,864 over the last ninety days. 4.40% of the stock is currently owned by insiders.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Jazz Pharmaceuticals wasn’t on the list.
While Jazz Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
Source: marketbeat.com
